699 results about "Control sample" patented technology

The invention provides methods of analyzing a nucleic acid in a target sample for variant alleles. In such methods, a first-labelled control sample and a second-labelled target sample are hybridized to at least one set of probes. The control sample comprises a homozygous reference allele. The target sample comprises the homozygous reference allele, or variant alleles differing from the reference allele at a locus, or one variant allele differing from the reference allele at the locus and one reference allele. The probes in the probe set span the locus and are complementary to the reference allele. After hybridization the intensity of first and second label bound to each probe in the set is measured. This information is then used to indicate the presence of one variant allele and one reference allele, or the presence of two variant alleles in the target sample.

An analyte test sensor for use in measuring the concentration of a particular analyte in a test sample includes a non-conductive substrate, a reference electrode deposited on the substrate, a working electrode deposited on the substrate and a compensation electrode deposited on the substrate. The compensation electrode is provided with a resistive ladder and is designed to correct for test result inaccuracies which are the result of variances in the manufacturing of the test sensor. Specifically, in one embodiment, the compensation electrode corrects for test result inaccuracies in an analog manner by shunting a portion of the working current away from working electrode. In another embodiment, the compensation electrode corrects for test result inaccuracies in a digital manner by providing a calibration code which is proportional its resistance value. A batch of analyte test sensors are preferably manufactured in the following manner. An initial batch of the test sensors is constructed. Then, a limited sampling of the sensors is tested for accuracy using a control sample. Based on the test results, the resistance value of the compensation electrode for each remaining sensor in the batch is adjusted accordingly.

The present invention provides systems useful for the enrichment of analytes, for example, cells of selected types, including but not limited to blood cells, stem cells, and pathogens, in samples. The invention also provides methods for analyzing the condition of a patient based on characteristics identified through analysis of the analytes in case and control samples.

We describe herein a cell-based multiplexing technique called detectable cell barcoding (DCB). In DCB, each individual sample is labeled with a different DCB signature that distinguishes each sample by one or both of detected intensity or type of detection characteristic. The samples are then combined and analyzed for a detectable characteristic of interest (e.g., presence of an analyte). By employing multiple distinct DCB labels at varying concentrations, one can perform multiplex analyses on up to hundreds or thousands (or more) of cell samples in a single reaction tube. DCB reduces reagent consumption by factors of 100-fold or more, significantly reduces data acquisition times and allows for stringent control sample analysis.

A sample having a plurality of probe molecules is illuminated with at least one beam of excitation light that is linearly polarized along a first axis, thereby effecting fluorescence emission in a plurality of spectral bands. The intensity of a first component of fluorescence emission that is polarized along the first axis, as well as the intensity of a second component of fluorescence emission that is polarized along an orthogonal second axis, is measured for each of said plurality of spectral bands. These measurements are represented as a measurement vector M. Since each probe emits some limited amount of light in the characteristic band of another probe, this results in cross-talk between probes. The measurement vector is therefore corrected using an instrument response matrix A, which is generated by measuring the flux output of control samples which each have only a single probe species. A flux vector S is calculated according to S=A.sup.-1M, and the fluorescence polarization FP is calculated from the S values.

A method for identification of biological characteristics is achieved by collecting a data set relating to individuals having known biological characteristics and analyzing the data set to identify biomarkers potentially relating to selected biological state classes. A system for identification of biological characteristics is also provided. A methodology is also provided for utilizing mass spectroscopy data to identify peptide and protein biomarkers that can be used to optimally discriminate experimental from control samples—where the experimental samples may, for instance, be derived from patients with various diseases such as ovarian cancer.

The present invention discloses a method for diagnosing Irritable Bowel Syndrome (IBS) in a test sample by determining the level of several bacterial taxa in the test sample, comparing this level with the levels of those bacterial taxa in a control sample, and relating the level to a diagnosis of IBS. Additionally, the present invention provides a method for treatment of IBS based on said diagnosis. Also, the invention provides a method for subtyping IBS in a test sample.

A method for identifying and characterizing components of interest in complex samples includes subjecting both a sample and its control samples to chromatography/high resolution mass spectrometry analysis to detect ions of the samples. The method includes defining sections of control sample data within specified chromatographic fluctuation time and mass precision windows around each ion or each group of the same ions of question in the test sample data. The defined sections of the control sample data are examined and the maximal intensities are subtracted from respective ions in the test sample. Components of interest are determined from the resultant data of the test sample. The method can be used for identifying molecular ions and/or their fragment ions for components of interest in complex samples.

The invention discloses a new rice and old rice quality detection device and detection method based on a visual light, near-infrared and terahertz integrated spectrum technology. The detection device is composed of a halogen light source, a visual light-near-infrared hyperspectrum sensor, a transmission-type terahertz time-domain spectrum system, a rotation-type sample carrying device, a groove-type sample table, an electronic control detection rocker arm, electronic control sample table rocker arms, a computer, a data acquisition card, a control module, a mode switching button, a shading hood, an instrument rack and the like. When detection is conducted, visual light-near-infrared hyperspectra and terahertz spectra of a sample are collected through the mode switching button. An optimal characteristic wave band combination of the related visual light, near-infrared and terahertz integrated spectra which are stored in experiments is extracted and substituted into a related quantitative detection model, and qualitative results of the related new rice and old rice quality of the rice sample and related protein and amino acid are obtained and output. Accordingly, limitation generated when the new rice and old rice quality is detected through a single spectrum technique is broken through, and the detection device and detection method can be used for real-time storage quality detection on warehouse rice.

A noninvasive analyzer apparatus and method of use thereof is described for spatially separating light for use in noninvasively determining an analyte concentration of a subject through use of detectors linked to multiple controlled sample illumination zone to sample detection zone distances. The controlled radial separation of illumination and detection zones yields reduced deviation in total observed optical pathlength and/or control of pathlengths in a desired tissue volume for each element of a set of detector elements. Performance using the discrete detection zones is enhanced using a combination of segmented spacers, arcs of detector elements, use of micro-optics, use of optical filters associated with individual detector elements, control of detector response shapes, and/or outlier analysis achievable through use of multiple separate and related observed signals of a detector array.

A real-time continuous detector device for detection of contaminants in a sample includes at least one sample management module, including a mechanism to control sample flow management to place the sample on a sample area. At least one electronic module for data processing and control is provided, and there is at least one optical module consisting of at least one real-time replaceable sensor cartridge containing a plurality of sensors, and at least one real-time optical pathogen detector connected to the electronic module for data processing. Power is provided and the device is equipped with at least one secure communication module adapted to transmit encrypted information over a secure link to a remote location and for receiving information. The invention also discloses a system making use of detectors for real-time detection of contaminants and for early warning capability, among others.

The invention provides a circuit and a method for switch power supply feedback voltage detection and sampling and holding. The circuit provided by the invention comprises a clock control circuit, a control sampling clock, a sampling and holding circuit, a waiting state control circuit, a learning state control circuit, an increment control circuit, a system control circuit and a delay circuit, wherein the sampling and holding circuit samples an input voltage at different time in two paths and selects a larger value to be output; the waiting state control circuit controls sampling and waits till a waveform is stable; the learning state control circuit controls the time sequence of a learning state; the increment control circuit controls an increment circuit which realizes two adjacent times of sampling; the system control circuit controls a finite state machine together with other circuits; and the delay circuit realizes required delay. In the method of the invention, an entire switching period of a switch power supply is divided into five states in turn: a PWM open state, a waiting state, a learning state, a detection state and a demagnetization ending state; the five states form the finite state machine; and the detection and sampling and holding of a feedback voltage can be realized by controlling the state switching and output of the finite state machine.

The invention discloses a power quality monitoring method. A FPGA is employed in the method to realize zero-crossing detection function and compared with traditional voltage-controlled oscillators, the method exhibits better real-time performance and following performance. On frequency measurement and sampling control, three-phase voltage signal is introduced as a standard of the frequency measurement and the sampling control so that, compared with one-phase voltage signal introduced as the standard, the method is more reliable and flexible; that software controls sample interval is as a supplement of hardware sampling control, so that sampling accuracy is improved; on algorithm input points, accuracy requirement of the algorithm and the calculated quantity are balanced; and under the condition that accuracy is guaranteed, calculated quantity is lessened, so that cost performance of the actual device is improved.

The invention relates, in part, to methods of using proteomic biomarkers to diagnose preeclampsia. In some aspects the invention, in part, relates to the detection of serpina-1 polypeptide and/or albumin polypeptide in samples from pregnant subjects. Samples from subjects may be compared to control samples to diagnose preeclampsia and/or to determine the onset, progression, or regression of preeclampsia in a subject. The invention also relates, in part, to screening methods to identify agents that can be used to treat preeclampsia and to determine the efficacy of a preeclampsia treatment. The invention, in part, also includes kits that are useful to diagnose and assess preeclampsia in a subject.

In a clinical laboratory of a hospital, an enormous amount of effort has been required to maintain the quality of an analyzer, standard solution and control samples. An object of the present invention is to provide a control method for controlling a clinical laboratory with reduced cost, and a control apparatus using the same.

In order to control data of an analyzer, standard solution, and a control sample, a support center is connected to each analyzer located in each hospital through a network line. Various kinds of analysis parameters and the result of measurements are exchanged so as to provide each clinical laboratory with a control situation in real time.

The invention provides a method for screening for colorectal cancer, the method comprising: screening a biological sample from an individual for one or more biomarkers selected from the group defined in Table 1 and/or Table 6, wherein the presence of or increased expression of the one or more biomarkers relative to a control sample is indicative that the individual is at risk of suffering from or is suffering from colorectal cancer. The invention also provides an array and kit suitable for use in the methods of the invention, methods of treating colorectal cancer and therapeutic agents for use in methods of treating cancer.

The present invention relates to new methods for the specific detection, quantification and/or differential diagnosis of neurodegeneration in an individual making use of a combination assay detecting at least three neurological markers in one or more body fluids of said individual, the type and degree of neurodegeneration being reflected in the quantitative changes in the level of all of said neurological markers compared to the control sample. The present invention also relates to methods for the detection of Rab3a, SNAP25 and alpha-synuclein in cerebrospinal fluid and to the use of these methods in a combination assay for specific detection, quantification and/or differential diagnosis of neurodegeneration.

An apparatus (10) and method for use in a vertical flow-through assay process is characterised by applying pressure to a sample to force the sample through a reaction/capture membrane (12), to which one or more ligands are bound, at a controlled rate. Typically, the method includes a pre-incubation step in which the sample and a detection analyte typically an antibody bound to colloidal gold or a fluorescent tag bind together The pre-incubation step typically takes place in a chamber (26) spaced above the capture membrane (12). The base of the chamber is defined by a porous hydrophobic frit (34) typically formed from polyethylene. It is preferred that the chamber (26) is defined by the upper part of a cylinder (24) extending from a seal (30) compressing the reaction membrane (12) against an absorbent pad (28). The seal (30) has the effect of compressing tie reaction membrane and preventing wicking of the sample in the lateral direction outside of the circular seal. A piston (28) compresses air located in the chamber above atmospheric pressure to farce the sample to pass through the hydrophobic frit (34). Alternatively, a hydraulic actuator (60) may directly act on the sample to force the sample through the frit and reaction membrane at a predetermined rate.